Inhibrx Total Liabilities 2020-2022 | INBX

Inhibrx total liabilities from 2020 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Inhibrx Annual Total Liabilities
(Millions of US $)
2021 $98
2020 $68
2019 $120
Inhibrx Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $134
2021-12-31 $98
2021-09-30 $101
2021-06-30 $98
2021-03-31 $64
2020-12-31 $68
2020-09-30 $52
2020-06-30 $0
2020-03-31 $0
2019-12-31
2019-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.527B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00